GLP3-R
Em Estoque e Pronto para Envio dos EUA
Frete GRATIS em pedidos acima de US$200
Checkout seguro via processador de pagamento criptografado
Apenas para Uso em Pesquisa
Estes produtos sao destinados exclusivamente a pesquisa laboratorial e nao se destinam ao uso medico. Nao sao aprovados pela FDA para diagnosticar, tratar, curar ou prevenir qualquer doenca. Ao adquirir, voce certifica que os produtos serao utilizados exclusivamente para pesquisa e nao para consumo humano ou animal.
Resumo da Pesquisa
17 Citacoes PubMedVisao Geral da Pesquisa Retatrutide (LY3437943) is a first-in-class incretin-based triple hormone agonista do receptor developed by Eli Lilly and Company to address the limitations of current obesidade and diabetes tipo 2 therapeutics by simultaneamente engaging three distinct metabolic pathways. A molecula foi descrito(a) pela primeira vez by Coskun et al. in a 2022 publication in Cell Metabolism, detailing its discovery, mechanism, and proof of concept from modelos pre-clinicos through Phase 1 human data.[4] Structurally, retatrutide is a 39-aminoacido synthetic peptide engineered from a GIP peptide backbone. It incorporates three non-coded aminoacido residues — two α-aminoisobutyric acid (Aib) residues at positions 2 and 20, and one α-methyl-L-leucine residue at position 13 — para aprimorar metabolic stability and ligacao ao receptor. A C20 fatty diacid moiety is conjugated at lysine-17 via an AEEA-γGlu linker, promoting albumin binding and extending the plasma meia-vida to aproximadamente 6 days, enabling convenient uma vez por...
GLP3-R — Dados de Pesquisa em Resumo
| Propriedade | Valor |
|---|---|
| Citacoes PubMed Referenciadas | 17 |
| Pesquisadores Colaboradores | 3 |
| Condicoes de Armazenamento | Liofilizado: -20°C to -80°C (estável 1–2 anos); Reconstituído: alíquote e armazene a -20°C; evite congelamento-descongelamento repetido; proteja da umidade e da luz. |
| Padrao de Pureza | ≥99% (HPLC verified, 3rd-party COA) |
| Apenas para Uso em Pesquisa | Nao destinado ao consumo humano. Apenas para uso em pesquisa. |
Nesta Página
Visao Geral
Visao Geral da Pesquisa
Retatrutide (LY3437943) is a first-in-class incretin-based triple hormone agonista do receptor developed by Eli Lilly and Company to address the limitations of current obesidade and diabetes tipo 2 therapeutics by simultaneamente engaging three distinct metabolic pathways. A molecula foi descrito(a) pela primeira vez by Coskun et al. in a 2022 publication in Cell Metabolism, detailing its discovery, mechanism, and proof of concept from modelos pre-clinicos through Phase 1 human data.[4]
Structurally, retatrutide is a 39-aminoacido synthetic peptide engineered from a GIP peptide backbone. It incorporates three non-coded aminoacido residues — two α-aminoisobutyric acid (Aib) residues at positions 2 and 20, and one α-methyl-L-leucine residue at position 13 — para aprimorar metabolic stability and ligacao ao receptor. A C20 fatty diacid moiety is conjugated at lysine-17 via an AEEA-γGlu linker, promoting albumin binding and extending the plasma meia-vida to aproximadamente 6 days, enabling convenient uma vez por semana subcutaneo(a) administration.[4][8]
The foundational therapeutic rationale for retatrutide rests no(a) hypothesis que simultaneamente activating receptors for GLP-1, GIP, and glucagon can produce superior metabolic outcomes comparado(a) a mono- or dual-agonista do receptors. GLP-1 receptor agonism suprime appetite and estimula secrecao de insulina; GIP receptor agonism aprimora the insulinotropic response and apoia lipid metabolismo; and criticamente, glucagon receptor agonism aumenta energy expenditure and drives lipolysis and hepatico(a) fatty acid oxidation — a mechanism absent from existing dual agonists like tirzepatide.[1][10][11]
Clinical trials demonstraram remarkable efficacy. The pivotal Phase 2 trial by Jastreboff et al. (2023) no(a) New England Journal of Medicine relatado(a) dose-dependente perda de peso in adults with obesidade, reaching up to 24.2% mean peso corporal reduction at 48 weeks com o(a) 12 mg dose — and perda de peso nao tinha plateaued at study conclusion.[1] A parallel Phase 2 trial by Rosenstock et al. (2023) in The Lancet demonstrated HbA1c reductions of up to -2.02% in participants with diabetes tipo 2.[2] Phase 3 results do(a) TRIUMPH program have desde confirmou estes achados, with data showing up to 28.7% mean perda de peso at 68 weeks and significant relief from obesidade-related comorbidities incluindo knee osteoartrite.[5]
Beyond obesidade and diabetes, retatrutide is under investigation for metabolic dysfunction-associated steatotic doenca hepatico(a)a (MASLD), onde a Phase 2a substudy by Sanyal et al. (2024) publicado(a) em Nature Medicine demonstrated que the 8 mg and 12 mg doses normalized liver fat (<5%) in over 85% of participants, with relative reductions of up to 86% em relacao ao basal.[3] Additional ongoing Phase 3 trials are evaluating the drug for desfechos cardiovasculares (TRIUMPH-OUTCOMES), cronico(a) doenca renal (TRANSCEND-CKD), obstructive sleep apnea, and knee osteoartrite.[5][7][9] Preclinical research tambem tem revelou intriguing potential in obesidade-associated cancer progression, with Marathe et al. (2025) demonstrating que retatrutide reduziu tumor engraftment and retardou tumor onset, outperforming semaglutide in tumor supressao.[14]
Mecanismo de Acao
Mecanismo de Acao
Retatrutide functions como um(a) simultaneous triple G protein-coupled agonista do receptor, activating the GIP receptor, the GLP-1 receptor, e o(a) glucagon receptor from a single peptide molecule. This "Triple G" mechanism integrates appetite supressao, insulinotropic effects, and aprimorou energy expenditure into one pharmacological agent.[4][10]
Receptor Binding Properties
| Property | GIP Receptor (GIPR) | GLP-1 Receptor (GLP-1R) | Glucagon Receptor (GCGR) |
|---|---|---|---|
| Relative Potency (vs. endogenous ligand) | 8.9× aquele(a) de native GIP | 0.4× aquele(a) de native GLP-1 | 0.3× aquele(a) de native glucagon |
| EC50 (Human, In Vitro) | 0.0643 nM | 0.775 nM | 5.79 nM |
| EC50 (Mouse) | 0.191 nM | 0.794 nM | 2.32 nM |
| Design Profile | Highest potency — primary backbone origin | Attenuated — melhora GI tolerability | Attenuated — balanced by insulinotropic effects |
| Evidence | Coskun et al. (2022)[4] | Coskun et al. (2022)[4] | Coskun et al. (2022)[4] |
Downstream Signaling Cascade
| Step | Signaling Event | Molecular Detail |
|---|---|---|
| 1. Receptor Binding | Retatrutide liga-se a GIPR, GLP-1R, and/or GCGR on target cell membranes | All three are Gs-coupled GPCRs[4] |
| 2. G-Protein Coupling | Conformational change ativa Gs proteins | Stimulates adenylate cyclase[4] |
| 3. cAMP Elevation | Adenylate cyclase converts ATP to cyclic AMP (cAMP) | cAMP acts as second messenger[11] |
| 4. PKA Activation | Elevated cAMP ativa Protein Kinase A (PKA) and RAPGEF4 (Epac2) | Downstream effector ativacao[11] |
| 5. Ion Channel Modulation | In β-cells: closure of KATP channels, opening of voltage-gated Ca2+ channels | Ca2+ influx desencadeia insulin granule exocytosis[11] |
| 6. Gene Expression | Nuclear signaling promove insulin biosynthesis and β-proliferacao celular | Long-term metabolic adaptation[11] |
Tissue-Level Effects by Organ System
| Tissue / Organ | Effect | Primary Receptor(s) | Evidence |
|---|---|---|---|
| Pancreas (β-cells) | Glucose-dependent secrecao de insulinum(a) potenteiated | GLP-1R, GIPR | Coskun et al. (2022)[4] |
| Pancreas (α-cells) | Suppressed glucagon secretion during hiperglicemia (net glycemic improvement apesar de GCGR ativacao) | GLP-1R (suppressive), GCGR (counterbalanced) | Rosenstock et al. (2023)[2] |
| Liver | Increased mitochondrial fatty acid oxidation; reduziu hepatico(a) lipogenesis; up to 86% relative liver fat reduction | GCGR (primary), GLP-1R | Sanyal et al. (2024)[3] |
| Adipose Tissue | Increased energy expenditure; promoveu lipolysis in white tecido adiposo; melhorou lipid-buffering capacity | GCGR (lipolysis/EE), GIPR (lipid buffering) | Katsi et al. (2025)[10] |
| Central Nervous System | Hypothalamic appetite supressao and aprimorou satiety signaling | GLP-1R, GIPR | Abdul-Rahman et al. (2024)[11] |
| GI Tract | Delayed gastric emptying (atenua with cronico(a) dosing) | GLP-1R | Urva et al. (2023)[17] |
| Kidney | Potential renoprotective effects: reduziu albuminuria, melhorou renal hemodynamics over time | GLP-1R, indireto(a) (visceral fat reduction) | Heerspink et al. (2025)[7] |
Comparison with Related Compounds
| Caracteristica | Retatrutide (Triple Agonist) | Tirzepatide (Dual Agonist) | Semaglutide (Mono Agonist) |
|---|---|---|---|
| Receptor Targets | GLP-1, GIP, Glucagon | GLP-1, GIP | GLP-1 only |
| Glucagon Activity | Yes — aumenta energy expenditure & lipid oxidation | No | No |
| Primary Weight-Loss Mechanism | Appetite supressao + aumentou energy expenditure | Appetite supressao + metabolic regulacao | Appetite supressao |
| Weight Loss (Phase 2, 48 wks) | Up to 24.2%[1] | ~11–12% | ~15–17% (Phase 3, 68 wks) |
| Weight Loss (Phase 3) | Up to 28.7% at 68 wks[5] | ~20–22% (Phase 3) | ~15–17% (Phase 3) |
| Liver Fat Reduction (MASLD) | >85% resolution of steatosis[3] | Significant reduction | Significant reduction |
The addition of glucagon receptor agonism e o(a) critico(a) pharmacological differentiator. While glucagon would normally raise glicose sanguinea via hepatico(a) glycogenolysis, the strong insulinotropic effects of GIP and GLP-1 receptor ativacao "buffer" este efeito, allowing the metabolic benefits of glucagon signaling — aumentou energy expenditure, aprimorou lipolysis, and hepatico(a) fat oxidation — to be safely harnessed sem worsening hiperglicemia.[4][10]
Aplicacoes de Pesquisa
Aplicacoes de Pesquisa
Retatrutide is under ativo(a) preclinical and clinical investigation across 7+ principal research domains, leveraging its unique triple-agonista do receptor mechanism:
- Obesity and Weight Management — O(a) principal investigacional focus. Phase 2 trials (Jastreboff et al., 2023) demonstrated dose-dependente perda de peso up to 24.2% at 48 weeks com o(a) 12 mg dose, and perda de peso nao tinha plateaued at study conclusion.[1] Phase 3 TRIUMPH program data confirmou up to 28.7% mean perda de peso at 68 weeks (aproximadamente 71.2 lbs average), com o(a) 12 mg dose group showing the greatest reductions.[5] Estudos pre-clinicos in diet-induziu camundongos obesos demonstrated 36.9% peso corporal loss (vs. 21.2% for tirzepatide) with 86.8% massa gorda reduction.[4]
- Type 2 Diabetes Mellitus (T2D) — Rosenstock et al. (2023) demonstrated significant glycemic improvements in Phase 2, with HbA1c reductions of up to -2.02% no(a) 12 mg dose over 36 weeks, along with improvements in fasting glucose, sensibilidade a insulina, and beta-cell function.[2] Body composition substudies confirmou que perda de peso was primariamente driven by massa gorda reduction.[6]
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/NAFLD) — A Phase 2a substudy by Sanyal et al. (2024) publicado(a) em Nature Medicine demonstrated que the 8 mg and 12 mg doses normalized liver fat (<5%) in over 85% of participants, with relative liver fat reductions of up to 86% em relacao ao basal. Este efeito is linked to glucagon receptor-mediated aumenta in hepatico(a) fatty acid oxidation and elevated beta-hydroxybutyrate biomarcadors.[3]
- Cardiovascular Disease (CVD) — The TRIUMPH-OUTCOMES Phase 3 trial is assessing se retatrutide reduz a incidencia of principal adverse eventos cardiovasculares (MACE) in adults with obesidade and estabeleceu atherosclerotic doenca cardiovascular. Pre-trial data show dose-dependente heart rate aumenta que peak at 24 weeks before declining.[5][10]
- Chronic Kidney Disease (CKD) — The TRANSCEND-CKD trial is investigating retatrutide's effects on kidney structure and function, incluindo medido(a) glomerular filtration rate (mGFR). Post-hoc analyses from Phase 2 data suggested potential renoprotective effects, incluindo reduziu albuminuria and melhorou renal hemodynamics over time.[7][9]
- Knee Osteoarthritis (OA) — The TRIUMPH-4 Phase 3 trial evaluates retatrutide in subjects with obesidade and knee osteoartrite. Results showed a significant reduction in WOMAC pain scores (up to 75.8% improvement) and melhorou physical function, alongside substantial perda de peso.[5]
- Obstructive Sleep Apnea (OSA) — Included dentro do(a) TRIUMPH-1 and TRIUMPH-2 basket trials, research aims to determine retatrutide's efficacy in reducing the apnea-hypopnea index in subjects with obesidade.[5]
- Obesity-Associated Cancer — Preclinical research by Marathe et al. (2025) demonstrated que retatrutide-induziu perda de peso reduziu tumor engraftment, retardou tumor onset, and significantly atenuou tumor growth in pancreatic and lung cancer models, outperforming semaglutide. Antitumor effects persisted apesar de partial weight regain, suggesting durable sistemico(a) and tumor immune reprogramming.[14]
- Diabetic Kidney Disease (DKD) — Em estudos pre-clinicos, Ma et al. (2025) showed retatrutide demonstrated superior efficacy over liraglutide and tirzepatide in controlling risk factors associado(a) com diabetic doenca renal in db/db mice, effectively mitigating inflammatory and fibrotic processes.[15]
Clinical Efficacy Summary by Dose (Phase 2)
| Dose | Weight Loss (48 wks, Obesity) | HbA1c Reduction (36 wks, T2D) | Evidence |
|---|---|---|---|
| 1 mg | -8.7% | — | Jastreboff et al. (2023)[1] |
| 0.5 mg | — | -0.43% | Rosenstock et al. (2023)[2] |
| 4 mg | -17.1% | ~-1.3% | [1][2] |
| 8 mg | -22.8% | ~-1.9% | [1][2] |
| 12 mg | -24.2% | -2.02% | [1][2] |
Caracteristicas Bioquimicas
| Propriedade | Valor |
|---|---|
| Molecular Formula | C₂₂₁H₃₄₂N₄₆O₆₈ |
| Molecular Weight | 4731.33 Da |
| CAS Number | 2381089-83-2 |
| PubChem CID | 171390338 |
| Sequence (1-Letter) | Y-Aib-QGTFTSDYSI-αMeL-LDK-K*-AQ-Aib-AFIEYLLEGGPSSGAPPPS-NH₂ (* = Lys modified with AEEA-γGlu-C20 diacid) |
| Sequence (3-Letter) | Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-αMeLeu-Leu-Asp-Lys-Lys(AEEA-γGlu-C20 diacid)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ |
| Structure | 39-aminoacido linear peptide; GIP backbone; non-coded residues: Aib at positions 2 & 20, α-methyl-L-leucine at position 13; C20 fatty diacid conjugated at Lys-17 via AEEA-γGlu linker; C-terminus amidated |
| Origin | Synthetic peptide engineered from GIP (dependente de glicose insulinotropic polypeptide) backbone; developed by Eli Lilly and Company |
| Classification | Triple Incretin/Hormone Receptor Agonist (GLP-1/GIP/Glucagon) / Acylated Peptide / Investigational Drug |
| Half-Life | Aproximadamente 6 days in humans, supporting once-dosagem semanal |
| Bioavailability | Subcutaneous injection; Tmax 12–72 hours; albumin binding via C20 fatty diacid extends duration of action |
Identificadores
| Purity Standard | ≥99% by RP-HPLC (research grade) |
|---|---|
| Synonyms | Retatrutide, LY3437943, LY-3437943, RTT, GGG Tri-Agonist, Triple G, Triple Agonist, Reta Peptide |
| InChI Key | MLOLQJNKXBNWFW-JMUPIODPSA-N |
| Developer | Eli Lilly and Company (Indianapolis, IN, USA) |
Resumo da Pesquisa Pre-clinica
Preclinical & Clinical Research Summary
Key Preclinical (Animal) Studies
| Estudo | Modelo | Principais Achados | Ref |
|---|---|---|---|
| Coskun et al. (2022) Cell Metabolism | DIO C57/Bl6 mice; 10 nmol/kg daily SC | 36.9% peso corporal loss (vs. 21.2% tirzepatide); 86.8% massa gorda reduction; melhorou glicose sanguinea, insulin, ALT, liver triglycerides; engages all three receptors in vivo | [4] |
| Urva et al. (2023) Diabetes Obes. Metab. | C57/Bl6 camundongos obesos; 10 nmol/kg SC | Dose-dependent gastric emptying delay; cronico(a) treatment atenuou GI slowing (tachyphylaxis); superior weight/food intake reduction vs. semaglutide alone | [17] |
| Ma et al. (2025) Endocrine | Diabetic db/db mice; 10 nmol/kg daily SC, 10 weeks | Superior efficacy over liraglutide and tirzepatide in reducing ALT, AST, cholesterol, triglycerides, LDL; mitigou inflammatory and fibrotic processes in diabetic kidney | [15] |
| Marathe et al. (2025) NPJ Metab. Health Dis. | Pancreatic and lung cancer models in camundongos obesos | Reduced tumor engraftment; retardou tumor onset; greater tumor supressao do que semaglutide; durable antitumor effects apesar de partial weight regain | [14] |
Key Clinical (Human) Studies
| Estudo | Population / Design | Key Results | Ref |
|---|---|---|---|
| Urva et al. (2022) Lancet (Phase 1b) | T2D subjects; MAD, 0.5–12 mg SC weekly; RCT | Dose-dependent HbA1c and reducao de pesos; t1/2 ~6 days confirmou; GI AEs dose-related; bem tolerado(a) overall | [8] |
| Jastreboff et al. (2023) NEJM (Phase 2) | Adults with obesidade (no T2D); 1, 4, 8, 12 mg SC weekly; 48 wks; RCT | -24.2% mean perda de peso (12 mg); dose-dependente; not plateaued at 48 wks; GI AEs a maioria common | [1] |
| Rosenstock et al. (2023) Lancet (Phase 2) | Adults with T2D; 0.5–12 mg SC weekly; 36 wks; RCT | HbA1c -2.02% (12 mg); significant perda de peso; melhorou sensibilidade a insulina; bem tolerado(a) | [2] |
| Sanyal et al. (2024) Nature Med. (Phase 2a) | MASLD substudy; MRI-PDFF assessed liver fat; 48 wks | >85% alcancou liver fat normalization (<5%) at 8–12 mg doses; up to 86% relative liver fat reduction | [3] |
| TRIUMPH-4 (Phase 3, 2025) Eli Lilly Press Release | Obesity + knee OA; 9 & 12 mg SC weekly; 68 wks | Up to 28.7% mean perda de peso; WOMAC pain scores melhorou by up to 75.8%; primeiro(a) successful Phase 3 trial | [5] |
Safety Profile Summary
| Category | Detail | Incidence / Notes |
|---|---|---|
| Common GI AEs | Nausea, diarrhea, vomiting, constipation, diminuiu appetite | Nausea up to 63% at highest doses; dose-dependente; a maioria common during titration[12][13] |
| Skin Hyperesthesia | Increased skin sensitivity, dysesthesia, "skin pain" | Up to 7% (vs. 1% placebo) in Phase 2[10] |
| Heart Rate | Dose-dependent increase, peaking at 24 weeks before declining | Mild to moderate arrhythmias relatado(a)[10] |
| Serious AEs | Acute pancreatitis (single cases); gallbladder disease; hipotensao | SAE rate semelhante a placebo (~4–5%)[12] |
| Hepatic Safety | No hepatotoxicity signals; transient ALT/AST elevations resolved | Monitored in all trials[12] |
Dosage Summary
| Setting | Dose | Route / Schedule | Notes |
|---|---|---|---|
| In Vitro (EC50) | 0.0643 nM (GIPR), 0.775 nM (GLP-1R), 5.79 nM (GCGR) | Cell culture | Biased toward GIP potency[4] |
| Animal (Mice) | 10 nmol/kg daily | SC injection | Standard efficacy dosing; t1/2 21 h in mice[4] |
| Phase 1 (SAD) | 0.1–6 mg (dose unica) | SC injection | Safety/PK assessment[8] |
| Phase 2 (Maintenance) | 1, 4, 8, 12 mg | SC once weekly; titrated from 2 or 4 mg | Titration by 2–4 mg every 4 weeks[1][2] |
| Phase 3 (TRIUMPH) | Target doses: 9 mg and 12 mg | SC once weekly; iniciou at 2 mg | Ongoing registrational trials[5] |
Pharmacokinetic Profile
| Parametro | Valor | Notes |
|---|---|---|
| Half-life (Human) | ~6 days | Supports once-dosagem semanal[8] |
| Half-life (Mouse) | ~21 hours | Single 47 μg/kg dose[4] |
| Tmax | 12–72 hours | Post-SC dose in humans |
| Metabolism | Hepatic proteolise; fatty acid β-oxidation | No CYP450 interaction |
| Clearance (Mouse) | 11.22 mL/h/kg | CD-1 mice |
&x26A0;️ Important Disclaimer
This product is sold strictly for in-vitro research and laboratory use only. It nao e aprovado(a) por the FDA for human consumption, medical use, diagnostic use, or veterinary use. Bodily introduction of qualquer kind into humans or animals is strictly forbidden by law. All products are supplied as research chemicals only. The information provided here is compiled from revisado(a) por pares scientific literature e e intended solely for educational and informational purposes.
About This Research Profile
This research profile was compiled from revisado(a) por pares sources incluindo publications no(a) New England Journal of Medicine, The Lancet, Nature Medicine, Cell Metabolism, e outros(as) high-impact journals. All citations reference publicly available scientific literature. The profile is regularly reviewed and updated to reflect the latest research findings. Last reviewed: February 2026.
Autores e Atribuicao
Autor do Artigo
Tamer Coskun, MD, PhD
Tamer Coskun, MD, PhD, is a senior researcher at Eli Lilly and Company (Indianapolis, IN, USA) and um(a) principal figure no(a) discovery and precoce development of retatrutide (LY3437943). He served como o(a) lead author no(a) foundational 2022 publication in Cell Metabolism detailing a molecula's discovery, mecanismo de acao, and proof of concept from modelos pre-clinicos through Phase 1 human data. Dr. Coskun has been a senior or co-author on subsequente Phase 2 ensaios clinicos, incluindo substudies focusing on composicao corporal, eating behavior, and kidney parameters. His research contributions span the entire traducaoal pipeline of retatrutide, from molecular design through clinical validation. His key publications include "LY3437943, um(a) novo(a) triple glucagon, GIP, and GLP-1 agonista do receptor for glycemic control and perda de peso: From discovery to clinical proof of concept" (2022, Cell Metabolism) and "Effects of retatrutide on composicao corporal in people with diabetes tipo 2" (2025, The Lancet Diabetes & Endocrinology). Tamer Coskun is being referenced as one do(a) leading scientists envolveu in retatrutide research. De forma alguma este(a) médico(a)/cientista endossa ou defende a compra, venda ou uso deste produto por qualquer motivo. Não existe afiliação ou relação, implícita ou de outra forma, entre a FNTN Health e este(a) médico(a).
Ver Perfil Completo do Pesquisador →Autor de Revista Cientifica
Ania M. Jastreboff, MD, PhD
Ania M. Jastreboff, MD, PhD, e um(a) Associate Professor at Yale University School of Medicine (New Haven, CT, USA) and Director do(a) Yale Obesity Research Center. She served como o(a) lead investigator para o(a) pivotal Phase 2 ensaio clinico evaluating retatrutide for o tratamento of obesidade, publicado(a) em the New England Journal of Medicine in 2023. Her work demonstrated que the drug could achieve up to 24.2% mean peso corporal reduction over 48 weeks, establishing retatrutide as one of o(a) mais potente investigacional anti-obesidade agents. Dr. Jastreboff is reconhecido(a) como a leading clinical researcher no(a) incretin-based obesidade therapeutics field, having also led pivotal trials for tirzepatide e outros(as) novel agents. Her key publications include "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial" (2023, New England Journal of Medicine). Ania M. Jastreboff is being referenced as one do(a) leading scientists envolveu in retatrutide research. De forma alguma este(a) médico(a)/cientista endossa ou defende a compra, venda ou uso deste produto por qualquer motivo. Não existe afiliação ou relação, implícita ou de outra forma, entre a FNTN Health e este(a) médico(a).
Ver Perfil Completo do Pesquisador →Ania M. Jastreboff, MD, PhD is being referenced as one of the leading scientists involved in the research and development of GLP3-R. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between FNTN Health and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.
Pesquisador Colaborador
Julio Rosenstock, MD
Julio Rosenstock, MD, is a clinical researcher affiliated with Velocity Clinical Research at Medical City (Dallas, TX, USA) e um(a) world-renowned expert in diabetes ensaios clinicos and incretin-based therapies. He led the Phase 2 ensaio clinico assessing a seguranca and efficacy of retatrutide in people with diabetes tipo 2, publicado(a) em The Lancet in 2023. His research highlighted the drug's ability to provide robust, dose-dependente reductions in ambos(as) HbA1c (up to -2.02%) and peso corporal comparado ao placebo e o(a) ativo(a) comparator dulaglutide. Dr. Rosenstock has been a principal investigator on numerosos(as) landmark diabetes drug trials and has authored hundreds of revisado(a) por pares publications. His key publications include "Retatrutide, a GIP, GLP-1 and glucagon agonista do receptor, for people with diabetes tipo 2: a randomised, duplo-cego, placebo and active-controlled, parallel-group, phase 2 trial conducted no(a) USA" (2023, The Lancet). Julio Rosenstock is being referenced as one do(a) leading scientists envolveu in retatrutide research. De forma alguma este(a) médico(a)/cientista endossa ou defende a compra, venda ou uso deste produto por qualquer motivo. Não existe afiliação ou relação, implícita ou de outra forma, entre a FNTN Health e este(a) médico(a).
Ver Perfil Completo do Pesquisador →Julio Rosenstock, MD is being referenced as one of the leading scientists involved in the research and development of GLP3-R. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between FNTN Health and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.
Citacoes Referenciadas
Jastreboff AM, Kaplan LM, Frias JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine, 389(6), 514-526, 2023.
PubMedRosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. Retatrutide, a GIP, GLP-1 and glucagon agonista do receptor, for people with diabetes tipo 2: a randomised, duplo-cego, placebo and active-controlled, parallel-group, phase 2 trial conducted no(a) USA. Lancet, 402(10401), 529-544, 2023.
DOISanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone agonista do receptor retatrutide for metabolic dysfunction-associated steatotic doenca hepatico(a)a: a randomizado phase 2a trial. Nature Medicine, 30(7), 2037-2048, 2024.
DOICoskun T, Urva S, Roell WC, Qu H, Loghin C, Moyers JS, O'Farrell LS, Briere DA, Sloop KW, Thomas MK, Pirro V, Wainscott DB, Willard FS, Abernathy M, Morford L, Du Y, Benson C, Gimeno RE, Haupt A, Milicevic Z. LY3437943, um(a) novo(a) triple glucagon, GIP, and GLP-1 agonista do receptor for glycemic control and perda de peso: From discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234-1247.e9, 2022.
DOIGiblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q, Lalonde A, Ahmad N, Bethel MA. Retatrutide for o tratamento of obesidade, obstructive sleep apnea and knee osteoartrite: Rationale and design do(a) TRIUMPH registrational ensaios clinicos. Diabetes, Obesity and Metabolism, 28(1), 83-93, 2026.
DOICoskun T, Wu Q, Schloot NC, Haupt A, Milicevic Z, Khouli C, Harris C. Effects of retatrutide on composicao corporal in people with diabetes tipo 2: a substudy of a phase 2, duplo-cego, parallel-group, controlado por placebo, randomised trial. The Lancet Diabetes & Endocrinology, 13(8), 674-684, 2025.
DOIHeerspink HJL, Lu Z, Du Y, Duffin KL, Coskun T, Haupt A, Hartman ML. The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity. Kidney International Reports, 10(6), 1980-1992, 2025.
DOIUrva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, um(a) novo(a) triple GIP, GLP-1, and glucagon agonista do receptor in people with diabetes tipo 2: a phase 1b, multicentre, duplo-cego, controlado por placebo, randomised, multiplos(as)-ascending dose trial. Lancet, 400(10366), 1869-1881, 2022.
DOIHeerspink HJL, van Raalte DH, Bjornstad P, Bunck MC, Wu P, Tunali I, Milicevic Z, Koeneman L. Rationale, design and caracteristicas basais do(a) TRANSCEND-CKD trial of retatrutide in patients with cronico(a) doenca renal. Nephrology Dialysis Transplantation, gfaf230, 2025.
DOIKatsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K. Retatrutide - A Game Changer in Obesity Pharmacotherapy. Biomolecules, 15(6), 796, 2025.
DOIAbdul-Rahman T, Roy P, Ahmed FK, Mueller-Gomez JL, Sarkar S, Garg N, Femi-Lawal VO, Wireko AA, Thaalibi HI, Hashmi MU, Dzebu AS, Banimusa SB, Sood A. The power of three: Retatrutide's role in modern obesidade and diabetes therapy. European Journal of Pharmacology, 985, 177095, 2024.
DOIMaharshi V, Singh S, Manjhi PK, Singh SK, Kumar A, Kumar R. Navigating retatrutide safety: comprehensive insights from revisao sistematica and meta-analise. Journal of Public Health and Development, 24(1), 318-338, 2026.
DOIAbouelmagd AA, Abdelrehim AM, Bashir MN, Abdelsalam F, Marey A, Tanas Y, Abuklish DM, Belal MM. Efficacy and safety of retatrutide, um(a) novo(a) GLP-1, GIP, and glucagon agonista do receptor for obesidade treatment: a revisao sistematica and meta-analise of randomizado controlled trials. Proceedings (Baylor University Medical Center), 38(3), 291-303, 2025.
DOIMarathe SJ, Grey EW, Bohm MS, Joseph SC, Ramesh AV, Cottam MA, et al. Incretin triple agonist retatrutide (LY3437943) alleviates obesidade-associated cancer progression. NPJ Metabolic Health and Disease, 3(1), 10, 2025.
DOIMa J, Hu X, Zhang W, Tao M, Wang M, Lu W. Comparison of o efeitos of Liraglutide, Tirzepatide, and Retatrutide on diabetic doenca renal in db/db mice. Endocrine, 87(1), 159-169, 2025.
DOITewari J, Qidwai KA, Tewari A, Kaur S, Tewari V, Maheshwari A. Efficacy and safety of triple hormone agonista do receptor retatrutide para o(a) management of obesidade: a revisao sistematica and meta-analise. Expert Review of Clinical Pharmacology, 18(1-2), 51-66, 2025.
DOIUrva S, O'Farrell L, Du Y, Loh MT, Hemmingway A, Qu H, Alsina-Fernandez J, Haupt A, Milicevic Z, Coskun T. The novel GIP, GLP-1 and glucagon agonista do receptor retatrutide retarda gastric emptying. Diabetes, Obesity and Metabolism, 25(11), 2784-2788, 2023.
DOIAviso de Uso em Pesquisa
Apenas para Uso em Pesquisa
Apenas para Uso em Pesquisa (RUO). Nao destinado ao consumo humano, uso clinico, ou como medicamento, alimento, cosmetico ou dispositivo medico. Este produto nao foi avaliado pelo FDA e e fornecido exclusivamente para pesquisa laboratorial in vitro por profissionais qualificados.
Certificado de Analise
Cada lote é rigorosamente testado por laboratórios terceirizados credenciados (ISO 17025) para garantir pureza de 99%+.
Ultimo Relatorio de Laboratorio
Certificate pending
This batch’s certificate of analysis is not yet on file. It is published here as soon as the lab report lands.
Armazenamento e Manuseio
Resumo
Liofilizado: -20°C to -80°C (estável 1–2 anos); Reconstituído: alíquote e armazene a -20°C; evite congelamento-descongelamento repetido; proteja da umidade e da luz.
Pó Liofilizado
Store at -80°C for optimal estabilidade a longo prazo (aproximadamente 2 years) or at -20°C por até 1 year. Keep in sealed containers, protegeu from moisture and light, ideally under nitrogen atmosphere. The liofilizado form appears como um(a) white to off-white solid powder.
Solução Reconstituída
Dissolve in sterile water (soluble at 20 mg/mL with pH adjustment) or DMSO. Prepare working aliquots immediately upon reconstitution para prevenir repeated freeze-thaw cycles, que can inactivate o peptideo. Store aliquots at -20°C and use dentro de 1 month for best results.
Quality Control
Purity is assessed by RP-HPLC (targeting ≥99% for research grade). Molecular identity is confirmou by Mass Spectrometry (expected MW ~4731.33 Da). Additional characterization may include NMR spectroscopy (H-NMR) for structural verification. A C20 fatty diacid conjugation at Lys-17 aprimora metabolic stability in biological systems.
